Scale and sustainability of marine bioprospecting for pharmaceuticals

Ambio

Volumn 35, Issue 2, 2006, Pages 57-64

  Hunt, Bob ^a,b   Vincent, Amanda C J ^b,c  

^a Project Seashore   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Department of Marine Conservation ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DRUG;

ABEE METEORITE; ANTHROPOGENIC EFFECT; AQUATIC ORGANISM; CONSERVATION; DRUG; ENVIRONMENTAL ASSESSMENT; ENVIRONMENTAL IMPACT ASSESSMENT; SUSTAINABILITY;

ANIMAL; BIOLOGY; ENVIRONMENTAL PROTECTION; PLANT; REVIEW; SPECIES DIFFERENCE;

ANIMALS; BIOLOGICAL PRODUCTS; CONSERVATION OF NATURAL RESOURCES; MARINE BIOLOGY; PHARMACEUTICAL PREPARATIONS; PLANTS; SPECIES SPECIFICITY;

EID: 33646396192     PISSN: 00447447     EISSN: None     Source Type: Journal    
DOI: 10.1579/0044-7447(2006)35[57:SASOMB]2.0.CO;2     Document Type: Review

References (87)

1. Cragg, G.M. and Newman, D.J. 2001. Natural product drug discovery in the next millennium. Pharm. Biol. 39, 8-17.
2. Lev, E. 2003. Traditional healing with animals (zootherapy): medieval to present-day Levantine practice. J. Ethnopharmacol. 85, 107-118.
3. Vincent, A.C.J. 1996. The international trade in seahorses. TRAFFIC International, Cambridge, 163 pp.
4. Newman, D.J. and Cragg, G.M. 2004. Marine natural products and related compounds in clinical and advanced preclinical trials. J. Nat. Prod. 67, 1216-1238.
5. Haefner, B. 2003. Drugs from the deep: marine natural products as drug candidates. Drug Discovery Today 8, 536-544.
6. Mayer, A.M.S. and Lehmann, V.K.B. 2000. Marine pharmacology. Pharmacologist. 42, 62-69.
7. Cragg, G.M., Newman, D.J. and Snader, K.M. 1997. Natural products in drug discovery and development. J. Nat. Prod. 60, 52-60.
8. Newman, D.J., Cragg, G.M. and Snader, K.M. 2003. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66, 1022-1037.
9. Proksch, P., Edrada-Ebel, R.A. and Ebel, R. 2003, Drugs from the sea - opportunities and obstacles. Marine Drugs 1, 5-17.
10. Kerr, R.G. and Kerr, S.S. 1999. Marine natural products as therapeutic agents. Expert Opin. Ther. Pat. 9, 1207-1222.
11. Olivera, B.M. 2000. ω-Conotoxin MVIIA: from marine snail venom to analgesic drug. In: Drugs from the Sea. Fusetani, N. (ed.). Karger, Basel, pp. 74.
12. Rinehart, K., Holt, T.G., Fregeau, N.L., Stroh, J.G., Kiefer, P.A., Sun, F., Li, L. and Martin, D.G. 1990. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J. Org. Chem. 55, 4512-4515.
13. Hooper, J.N.A., Quinn, R.J. and Murphy, P.T. 1998. Australian biodiversity via its plants and marine organisms. A high throughput screening approach to drug discovery. In: Biodiversity, Biotechnology & Biobusiness. 2nd Asia-Pacific Conference on Biotechnology. Van Keulen, M. and Borowizka, M.A. (eds.). Murdoch University, Perth, p. 519-526.
14. Eisner, T. 1989. Prospecting for nature's chemical riches. Issues Sci. Technol. 6, 31-34.
15. Rausser, G.C. and Small, A.A. 2000. Valuing research leads: bioprospecting and the conservation of genetic resources. J. Polit. Econ. 108, 173-206.
16. Zilinskas, R.A. and Lundin, C.G. 1993. Marine biotechnology and developing countries. The International Bank for Reconstruction and Development. Washington, DC, 116 pp.
17. Simpson, R.D. 1997. Biodiversity prospecting: Shopping the wilds is not the key to conservation. Resources 126, 12-15.
18. Firn, R.D. 2003. Bioprospecting - why is it so unrewarding? Biodivers. Conserv. 12, 207-216.
19. Anonymous. 1998. The complex realities of sharing genetic assets. Nature 392, 525.
20. Macilwain, C. 1998. When rhetoric hits reality in debate on bioprospecting. Nature 392, 535-540.
21. Dhillion, S.S. and Amundsen, C. 2000. Bioprospecting and the maintenance of biodiversity. In: Responding to bioprospecting: from biodiversity in the south to medicines in the north. Svarstad, H. and Dhillion, S.S. (eds.). Spartacus Forlag A/S, Oslo, p. 103.
22. Pinheiro, C.U. 1997. Jaborandi (Pilocarpus sp., Rutaceae): A wild species and its rapid transformation into a crop. Econ. Bot. 51, 49-58.
23. Garson, M. 1997. Biodiversity and bioprospecting. Australasian J. Nat. Resour. Law Policy 4, 227-239.
24. Benkendorff, K. 2002. Potential conservation benefits and problems associated with bioprospecting in the marine environment. In: A zoological revolution: using native fauna to assist in its own survival. Lumley, D. and Dickman, C. (eds.). Royal Zoological Society of New South Wales and Australian Museum, Sydney, p. 90.
25. Chivian, E., Roberts, C.M. and Bernstein, A.S. 2003. The threat to cone snails. Science 302, 391.
26. National Cancer Institute. 2000. Questions and Answers About NCI's Natural Products Branch. http://cis.nci.nih.gov/fact/7_33.htm
27. Natural Products Branch, Natural Cancer Institute. DTP - Natural Product Extract Cancer Screening Data. http://dtp.nci.nih.gov/docs/cancer/ natural_products/natural_products_data.html
28. PharmaMar. 2002. Annual Report. http://www.pharmamar.com/en/pdf/annual- report-2002-en.pdf
29. Quinn, R.J., de Almeida Leone, P., Guymer, G. and Hooper, J.N.A. 2002. Australian biodiversity via its plants and marine organisms. A high throughput screening approach to drug discovery. Pure Appl. Chem. 74, 519-526.
30. Munro, M.H.G., Blunt, J.W., Dumdei, E.J., Hickford, S.J.H., Lill, R.E., Li, S., Battershill, C.N. and Duckworth, A. R. 1999. The discovery and development of marine compounds with pharmaceutical potential. J. Biotechnol. 70, 15-25.
31. Harper, M.K., Bugni, T.S., Cropp, B.R., James, R. D., Lindsay, B.S., Richardson, A.D., Schnabel, P. C., Tasdemir, D., et al. 2001. Introduction to the chemical ecology of marine natural products. In: Marine Chemical Ecology. McClintock, J.B. and Baker, B.J. (eds.). CRC Press, Boca Raton, FL, p. 3-69.
32. Cordell, G.A. 2000. Biodiversity and drug discovery - a symbiotic relationship. Phytochemistry 55, 463-480.
33. Kuhlmann, J. 1997. Drug research: from the idea to the product. Int. J. Clin. Pharmacol. Ther. 35, 541-552.
34. Brixner, D. 1993. Biotechnology products: an overview. In: Biotechnology and pharmacy. Pezzuto, J.M., Johnson, M.E. and R, M. H. (eds.). Chapman and Hall, London, p. 381-401.
35. DiMasi, J.A. 2001. New drug development in the United States from 1963 to 1999. Clin. Pharmacol. Ther. 69, 286-296.
36. DiMasi, J.A., Hansen, R.W. and Grabowski, G. 2003. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185.
37. DiMasi et al. (36) estimate the average "out of pocket" costs of bringing a drug to market were $403 million in US dollars (in 2000 dollars). Capitalizing the cost with a real discount rate of 11% ["the expected return that investors forego during development when they invest in pharmaceutical R & D instead of an equally risky portfolio of financial securities" (36, p. 161) - the "cost-of-capital"] brought the total to $802 million in US dollars, and when postapproval research and development is included the estimated total was $897 million. The average approval date for drugs in the study was 1997. The authors estimated that if a drug was approved by 2001, the preapproval capitalized cost would be $1.1 thousand million, and for research and development initiated in 2001, the total capitalized costs given approval after 12 y would be $1.9 thousand million.
38. Cragg, G.M. 1998. Paclitaxel (Taxol): a success story with valuable lessons for natural product drug discovery and development. Med. Res. Rev. 18, 315-331.
39. Faulkner, D.J. 2000. Marine pharmacology. Anton. van Leeuw. 77, 135-145.
40. Mendola, D. 2003. Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: process developments and economics. Biomol. Eng. 20, 441-458.
41. Our primary resource was an online journal database maintained by the American Chemical Society (http://pubs.acs.org/journals/query/subscriberSearch. jsp), which we searched with the terms "marine," "collection, " and "secondary collection." Other databases, such as EMBASE (Excerpta Medica database), or search engines such as Google, revealed little information. Comparatively few articles reported wet weights, with many giving freeze-dried, frozen, or extracted amounts in the experimental section. The dearth of data, combined with the excessive influence of a few reports on very large collections, eliminated the possibility of making any meaningful assessment of the claimed decreasing temporal trends in (re)collection sizes. Previous studies have also found that researchers seldom report collected sizes and usually nothing about natural abundance within the collection area (24). The few published sample size data were usually associated with the discovery and description of a novel compound, with little information about the entire primary collection procedures or ongoing collections for the development of "lead" compounds.
42. Farrier, D. and Tucker, L. 2001. Access to marine bioresources: hitching the conservation cart to the bioprospecting horse. Ocean Dev. Int. Law 32, 213-239.
43. Voumard, J. (Inquiry Chair). 2000. Commonwealth Public Inquiry into Access to Biological Resources in Commonwealth Areas. Department of Environment and Heritage, Canberra, Australia, 306 pp.
44. Mendola, D. 2000. Aquacultural production of bryostatin 1 and Ecteinascidian 743. In: Drugs from the sea. Fusetani, N. (ed.). Karger, Basel, p. 120-133.
45. Hart, J.B., Lill, R.E., Hickford, S.J.H., Blunt, J.W. and Munro, M.H.G. 2000. The halichondrins: chemistry, biology, supply and delivery. In: Drugs from the sea. Fusetani, N. (ed.). Karger, Basel, p. 134-154.
46. Pettit, G.R., Leet, J.E., Herald, C.L., Kamano, Y., Boettner, F.E., Baczynskyj, L. and Nieman, R.A. 1987. Antineoplastic agents. 126. Isolation and structure of bryostatins 12 and 13. J. Org. Chem. 52, 2854-2860.
47. Pettit, G.R., Gao, F., Blumberg, P.M., Herald, C.L., Coll, J.C., Kamano, Y., Lewin, N.E., Schmidt, J.M., et al. 1996. Antineoplastic agents. 340. Isolation and Structural Elucidation of Bryostatins 16-18. J. Nat. Prod. 59, 286-289.
48. Pettit, G.R., Inoue, M., Kamano, Y., Herald, D.L., Arm, C., Dufresne, C., Christie, N.D., Schmidt, J.M., et al. 1988. Antineoplastic agents. 147. Isolation and structure of the powerful cell growth inhibitor cephalostatin. J. Am. Chem. Soc. 110, 2006-2008.
49. Pettit, G.R., Knight, J.C., Collins, J.C., Herald, D.L., Pettit, R.K., Boyd, M.R. and Young, V.G. 2000. Antineoplastic agents 430. Isolation and structure of cribrostatins 3, 4, and 5 from the Republic of Maldives cribrochalina species. J. Nat. Prod. 63, 793-798.
50. Pettit, G.R., Chicacz, Z.A., Gao, F., Herald, C.L., Boyd, M.R., Schmidt, J.M. and Hooper, J.N.A. 1993. Antineoplastic agents. 257. Isolation and structure of spongistatin. J. Org. Chem. 58, 1302-1304.
51. Pettit, G.R., Cichacz, Z.A., Tan, R., Hoard, M.S., Melody, N. and Pettit, R.K. 1998. Antineoplastic agents. 386. Isolation of sesterstatins 1-3 from the marine sponge Hyrtios erecta. J. Nat. Prod. 61, 13-16.
52. Pettit, G. R., Gao, F., Cerny, R.L., Doubek, D.L., Tackett, L.P., Schmidt, J.M. and Chapuis, J.-C. 1994. Antineoplastic agents. 278. Isolation and structure of axinastatins 2 and 3 from a western Caroline Island marine sponge. J. Med. Chem. 37, 1165-1168.
53. Chivian, E., Roberts, C.M., and Bernstein, A.S. 2004. Response (to Duda et al. 2004) Science 303, 956.
54. Duda, T.F.J., Bingham, J.-P., Livett, B.G., Kohn, A.J., Massilia, G.R., Schultz, J.R., Down, J., Sandall, D., et al. 2004. How much at risk are cone snails? Seienee 303, 955.
55. Marsh, H. and Kenchington, R. 2004. The role of ethics in experimental marine biology and ecology. J. Exp. Mar. Biol. Ecol. 300, 5-14.
56. Marsh, H. and Eros, C. M. 1999. Ethics of field research: do journals set the standard. Sci. Eng. Ethics 5, 375-382.
57. Janzen, D.H., Hallwachs, W., Gamez, R., Sittenfield, A. and Jimenez, J. 1993. Research management policies: permits for collecting and research in the tropics. In: Biodiversity Prospecting: Using Genetic Resources for Sustainable Development. World Resources Institute, Washington, D.C., p. 131-158
58. Cragg, G.M., Baker, B.J., Borris, R.P., Carte, B., Cordell, G.A., Soejarto, D.D., Gupta, M.P., Iwu, M.M., et al. 1997. Interactions with source countries. Guidelines for members of the American Society of Pharmacognosy. J. Nat. Prod. 60, 654-655.
59. Secretariat of the Convention on Biological Diversity. 2002. Bonn Guidelines on Access to Genetic Resources and Fair and Equitable Sharing of the Benefits Arising Out of Their Utilization. Secretariat of the Convention on Biological Diversity, Montreal, Canada, 20 pp.
60. Amundsen, C. 2000. Methodologies of biodiversity inventories and prospecting in Costa Rica: the case of INBio. Candidata Agriculturae Thesis, Agricultural University of Norway, Oslo, 83 pp.
61. ASTEC. 1998. Environmental Research Ethics: National Principles and Guidelines for the Ethical Conduct of Research in Protected and Environmentally Sensitive Areas. Australian Science Technology and Engineering Council, Canberra, Australia. http://www.dest.gov.au/archive/Science/astec/ethics/ethics. html
62. Pomponi, S.A. 1999. The bioprocess - technological potential of the sea. J. Biotechnol. 70, 5-13.
63. Schwartsmann, G., Da Rocha, A., Mattei, J. and Lopes, R. 2003. Marine derived anticancer agents in clinical trial. Expert Opin. Inv. Drug. 12, 1367-1383.
64. Cuevas, C., Pérez, M., Martín, M.J., Chicharro, J.L., Fernández-Rivas, C., Flores, M., Francesch, A., Gallego, P., et al. 2000. Synthesis of Ecteinascidian ET-743 and Phthalascidin Pt-650 from Cyanosafracin B. Org. Lett. 2, 2545-2548.
65. Lopez-Macia, A., Jimenez, J.C., Royo, M., Giralt, E. and Alberico, F. 2001. Synthesis and structure determination of Kahalalide F. J. Am. Chem. Soc. 123, 11398-11401.
66. McHugh, D.J. 2003. A guide to the seaweed industry. FAO fisheries technical paper 441. Food and Agriculture Organization of the United Nations, Rome.
67. Milanese, M., Chelossi, E., Manconi, R., Sidri, M., Sara, A. and Pronzato, R. 2003. Chondrilla nucula as an elective candidate for bioremediation in integrated aquaculture. Biomol. Eng. 20, 363-368.
68. Ganesan, A. 2001. Integrating natural product synthesis and combinatorial chemistry. Pure Appl. Chem. 73, 1033-1039.
69. Rouhi, A.M. 2003. Moving beyond natural products. Chem. Eng. News. October 13, 104-107.
70. GPC Biotech. GPC Biotech In-Licenses First Clinical Oncology Compound from Arizona State University. http://www.gpc-ag.com/site_usa/news/2001/01nov05. htm
71. Jensen, P.R. and Fenical, W. 2000. Marine microorganisms and drug discovery: current status and future potential. In: Drugs from the Sea. Fusetani. N. (ed.). Karger, Basel, p. 6-29.
72. Proksch, P., Edrada, R.A. and Ebel, R. 2002. Drugs from the sea - current status and microbiological implications. Appl. Microbiol. Biot. 59, 125-134.
73. Anonymous. 2002. Biorespecting in New Zealand. Discussing the options. Resources and Networks Branch, Ministry of Economic Development, Wellington, New Zealand, 36 pp.
74. Green, J.J. 2003. Report on the workshop in bioprospecting in the high seas. In: Interim Summary. Deep Sea 2003 Conference, 1-5 December. Queenstown, New Zealand, p. 29.
75. Lohan, D. and Johnston, S. 2003. The international regime for biorespecting: existing policies and emerging issues for Antarctica. United Nations University and Institute of Advanced Studies (UNU IAS), Tokyo, 26 pp.
76. Kong, H., Kucera, R.B. and Jack, W.E. 1993. Characterization of a DNA polymerase from the hyperthermophile archaea Thermococcus litoralis. J. Biol. Chem. 268, 1965-1975.
77. Glowka, L. 2001. Establishing the legal basis to conserve and sustainably use hydrothermal vents and their biological communities. In: Management and Conservation of Hydrothermal Vent Ecosystems. Dando, P. and Juniper, S.K. (eds.) InterRidge, Institute of Ocean Sciences, Victoria, Canada, p. 15-21.
78. Canadian Legal Information Institute. 2003, c. 20 (Bill C-42). http://www.canlii.org/ca/ as/2003/c20
79. Swiderska, K., Dano, E. and Dubois, O. 2001. Developing the Philippines' Executive Order No. 247 on Access to Genetic Resources. Participation in access and benefit-sharing policy. Case study No. 4. International Institute for Environment and Development. London, 39 pp.
80. Queensland Government. 2003. Exposure Draft of Biodiversity Discovery Bill 2003, (Obtained from Peter Cronin, Principal Policy Officer, Queensland Department of Primary Industries, in litt. 20 November 2003).
81. Rouhi, A.M. 2003. Betting on natural products for cures. Chem. Eng. News. October 13, 93-103.
82. Pitcher, C.R., Poiner, I.R., Hill, B.J. and Burridge, C.Y. 2000. Implications of the effects of trawling on sessile megazoobenthos on a tropical shelf in northeastern Australia. ICES J. Mar. Sci. 57, 1359-1368.
83. B. neritina has been successfully maricultured, and this technology could be used for future supply [see Mendola (40)].
84. Supply source was not confirmed at time of writing, although researchers have synthesized N-Boc derivatives of sinulosine: Yun, J. M., Sim, T.B., Heung, S.H. and Lee, W.K. 2003. Efficient synthesis of enantiomerically pure 2-cylaziridines: facile syntheses of N-Boc-safingol, N-Boc-D-erythro- sphinganine, and N-Boc-spisulosine from a common intermediate. J. Org. Chem. 68, 7675-7680.
85. Natural Products Repository, maintained by the Natural Products Branch of the US National Cancer Institute. http://dtp.nci.nih.gov.docs/cancer/ natural_products/natural_products_data.html
86. This is a contribution from Project Seahorse. We sincerely thank Robyn Forrest for her useful comments, Melissa Grey, Anne-Marie Biais, other Project Seahorse team members, and David Newman from NCI. We thank the three anonymous reviewers and the editor. This research was supported by the Pew Fellows Program in Marine Conservation (Pew Charitable Trust, USA) and by the John G. Shedd Aquarium (Chicago, IL, USA) in its marine conservation partnership with Project Seahorse.
87. First submitted 10 Feb. 2005. Accepted for publication 16 March 2005.